文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

局部晚期宫颈癌根治性放化疗及图像引导自适应近距离放疗后下肢水肿:EMBRACE研究

Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study.
PubMed 文献 · Radiother Oncol · 2018-04-06

基于前瞻性多中心EMBRACE研究,评估1176例局部晚期宫颈癌患者根治性放化疗及MRI引导近距离放疗后下肢水肿的表现模式与危险因素。中位随访27个月,医生评估CTCAE G≥1的3/5年发生率为27%/31%,患者报告任何症状的患病率随时间从25%升至34%。严重水肿罕见,但轻度水肿风险可观,与患者、诊断及治疗特征相关。

要点

  • 医生评估CTCAE G≥1下肢水肿3/5年发生率为27%/31%,G≥3仅0.5%。
  • 患者报告任何下肢水肿症状的患病率3个月至5年从25%升至34%,呈持续增加。
  • 侵入性淋巴结分期和诊断时肥胖是G≥1下肢水肿的独立显著危险因素。

核心结论

  • 局部晚期宫颈癌根治性放化疗后严重下肢水肿罕见,但轻度下肢水肿风险可观。
  • 下肢水肿与患者、诊断及治疗特征相关,侵入性淋巴结分期和肥胖是独立危险因素。

研究设计与样本

  • 前瞻性、观察性、多中心EMBRACE研究,纳入1176例接受放化疗及MRI引导近距离放疗的局部晚期宫颈癌患者。
  • 中位随访27个月,基线及定期随访时采用医生报告的CTCAE v.3和患者报告的EORTC QLQ-CX24问卷评估下肢水肿。

主要发现

  • 医生评估CTCAE G≥1的3/5年发生率为27%/31%,G≥2为6.1%/6.6%,G≥3为0.5%/0.5%。
  • 医生评估G≥1下肢水肿在治疗结束后3个月、1年、3年、5年的患病率分别为7%、12%、12%、15%。
  • 患者报告任何下肢水肿症状在相应时间点的患病率分别为25%、30%、30%、34%,呈持续增加。
  • 侵入性淋巴结分期和诊断时肥胖是G≥1下肢水肿的独立显著危险因素,淋巴结推量无影响。
  • 扩大放疗野包括腹主动脉旁和/或腹股沟淋巴结有增加风险的倾向。

关键数值与推荐

  • 医生评估CTCAE G≥1下肢水肿3/5年发生率为27%/31%,G≥2为6.1%/6.6%,G≥3为0.5%/0.5%。
  • 患者报告任何下肢水肿症状3个月、1年、3年、5年患病率分别为25%、30%、30%、34%。

临床怎么用

  • 应重视局部晚期宫颈癌放化疗后轻度下肢水肿的长期随访与患者报告症状评估。
  • 对接受侵入性淋巴结分期或诊断时肥胖的患者,可加强下肢水肿监测与康复干预。
  • 未来可探索减少侵入性诊断手术、非侵入性评估、减少侵入性放疗管理及积极康复。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/PURPOSE: To evaluate the pattern of manifestation and risk factors for lower limb edema (LLE) within the prospective, observational, multi-center EMBRACE study on radiochemotherapy and MRI-guided brachytherapy in locally advanced cervical cancer (LACC). MATERIAL/METHODS: LLE was prospectively assessed according to the physician-reported CTCAE v.3 and patient-reported EORTC QLQ-CX24 questionnaire at baseline and regular follow-up. RESULTS: In total, 1176 patients were evaluated with a median follow-up of 27 months. Actuarial analyses revealed 3/5-year estimates of 27%/31% of CTCAE G ≥ 1, 6.1%/6.6% of G ≥ 2 and 0.5%/0.5% for G ≥ 3. Prevalence rates for G ≥ 1 LLE at 3 months, 1, 3 and 5 years after end of treatment were 7%, 12%, 12%, 15% for physician-assessed and 25%, 30%, 30%, 34% for any patient-reported symptoms and showed a steady increase over time. Invasive lymph node staging and obesity at diagnosis are independent significant risk factors for G ≥ 1 LLE, whereas nodal boost has no impact. Extended radiation fields including para-aortic and/or inguinal nodes show a tendency to increase the risk. CONCLUSION: Severe LLE after definitive radiochemotherapy in LACC is rare. However, the risk for mild LLE is considerable, and related to patient-, diagnostic- and treatment characteristics. Less invasive diagnostic surgical procedures or non-invasive assessment, less invasive radiotherapy management and active rehabilitation are important pathways for future developments.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Najjari Jamal D, Pötter R, Haie-Meder C, et al. Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study. Radiother Oncol. 2018. PMID: 29631933. doi:10.1016/j.radonc.2018.03.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。